Assembly Biosciences (ASMB) Cash from Investing Activities (2011 - 2026)

Assembly Biosciences' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$5.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 181.72% year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at -$125.4 million (down 525.42% YoY), while the FY2025 annual figure was -$113.5 million, down 382.46% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$5.4 million, down from $21.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $33.0 million in Q1 2022, with the low at -$158.3 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $10.0 million (2023), against an average of -$3.4 million.
• Peak annual rise in Cash from Investing Activities reached 416.95% in 2025, while the deepest fall reached 746.32% in 2025.
• Assembly Biosciences' Cash from Investing Activities stood at $16.6 million in 2022, then plunged by 641.32% to -$89.7 million in 2023, then surged by 92.53% to -$6.7 million in 2024, then soared by 416.95% to $21.2 million in 2025, then slumped by 125.36% to -$5.4 million in 2026.
• Business Quant data shows ASMB's Cash from Investing Activities at -$5.4 million in Q1 2026, $21.2 million in Q4 2025, and -$158.3 million in Q3 2025.